Short Description:
Hana Conlon, André Müller, Xinhe Liu , Esther Jun, Saud Sadiq. Presented at the 5th joint congress of ECTRIMS and ACTRIMS meeting held October 19-22 in Amsterdam.
MS patients with a progressive disease respond poorly to currently available anti-inflammatory disease modifying agents. Intrathecal administration of the antifolate drug methotrexate has a beneficial impact on the disease progression of severe primary and secondary progressive MS cases. Astrocytic activation and subsequent astrogliosis occur in progressive MS as well as in the cuprizone-induced model of corpus callosum demyelination and are considered to be hallmarks of scar formation in the CNS.
| Attachment | Size |
|---|---|
 Download Full Abstract (PDF) | 1.62 MB |